Showing results (91-100 of 226) with videos related to
Sort By:
Pageof 23
Blood|March 1, 1982
The contribution of blast cell properties to outcome variation in acute myeloblastic leukemia (AML)E A McCulloch, J E Curtis, H A Messner, et al.Blood|July 1, 1981
The heritable nature of clonal characteristics in acute myeloblastic leukemiaE A McCulloch, R N Buick, J E Curtis, et al.Blood|August 1, 1989
Production of growth factors by malignant lymphoma cell linesM Tweeddale, N Jamal, A Nguyen, et al.European Journal of Haematology|July 1, 1996
Intensive remission induction therapy for chronic myeloid leukemia in blast phase with a goal of post-remission bone marrow transplant--a pilot studyJ H Lipton, H A Messner, J E Curtis, et al.Blood|March 10, 2001
Replicative stress after allogeneic bone marrow transplantation: changes in cycling of CD34+CD90+ and CD34+CD90- hematopoietic progenitorsI Thornley, D R Sutherland, R Nayar, et al.European Journal of Radiology|November 18, 2024
Preparing radiology residents for breast MRI: A dual-site, resident-as-teacher feasibility projectL Cereser, F Sparascio, P Clauser, et al.Blood|September 1, 1990
Growth and detection of human bone marrow B-lineage coloniesK McGinnes, E Keystone, E Bogoch, et al.Bone Marrow Transplantation|August 1, 1994
Minimal residual disease in bone marrow transplant recipients with chronic myeloid leukemiaW M Xu, X H Piao, L Addy, et al.Hematology (Amsterdam, Netherlands)|May 15, 2003
Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemiasV Gupta, S Kamel-Reid, M D Minden, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantationT L Kiss, M Abdolell, N Jamal, et al.Pageof 23